Who
Ahmed Hamdy
Cmo
Company insider
Files Form 4 as: Cmo, Curis; Chief Executive Officer, Vincerx Pharma; Chief Medical Officer, Pharmacyclics.
In numbers
- Trades disclosed
- 47
- Buys
- 6
- Sells
- 1
- Bought
- $251K
- Sold
- $123K
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 10 Mar 2009
- Last trade
- 20 Mar 2026
- Last filed
- 23 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 20 Mar 2026filed 23 Mar 2026 | CRIS CurisBiotechnology | SEC FORM 4 Code C | —66,667 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code C | —50 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code C | —50 | filing |
| 20 Mar 2026filed 23 Mar 2026 | CRIS CurisBiotechnology | SEC FORM 4 Code C | —66,667 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —50 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,667 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,667 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —50 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,667 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,667 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,667 | filing |
| 17 Mar 2026filed 18 Mar 2026 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | —66,667 | filing |
| 1 May 2025filed 5 May 2025 | CRIS Curisoption or derivative · Biotechnology | SEC FORM 4 Code A | $496K200,000 at $2.48 | filing |
| 12 Aug 2024filed 14 Aug 2024 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code D | —127,500 | filing |
| 12 Aug 2024filed 14 Aug 2024 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code A | —127,500 | filing |
| 12 Aug 2024filed 14 Aug 2024 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 12 Aug 2024filed 14 Aug 2024 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code A | —60,000 | filing |
| 12 Aug 2024filed 14 Aug 2024 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 12 Aug 2024filed 14 Aug 2024 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code A | —60,000 | filing |
| 12 Aug 2024filed 14 Aug 2024 | Vincerx Pharmaoption or derivative | SEC FORM 4 Code D | —90,000 | filing |
News
No headline names them, or the companies they trade most, lately.